Study guide

3.2 Neonatal Hypoglycemia & Metabolic Problems

Arab Board Pediatrics Part 1 Written Examination ABHS

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current ABHS Pediatrics Part 1 Exam Facts 1.2 How to Use This Guide & Part 1 Study Strategy

2 Neonatal Care I

2.1 Delivery-Room Management & Neonatal Resuscitation 2.2 Prematurity & Complications of Prematurity 2.3 Neonatal Jaundice & Hyperbilirubinemia

3 Neonatal Care II

3.1 Neonatal Sepsis & Infections 3.2 Neonatal Hypoglycemia & Metabolic Problems 3.3 Common Newborn Problems, Birth Injury & Screening

4 Infectious Diseases

4.1 Fever Without a Source & Sepsis Evaluation 4.2 Viral Exanthems & Common Childhood Infections 4.3 TORCH & Congenital Infections 4.4 Tuberculosis & Chronic/Unusual Pediatric Infections

5 Immunization

5.1 Routine Immunization Schedule & Vaccine Science 5.2 Contraindications, Adverse Events & Special Populations

6 Allergy & Immunology

6.1 Primary Immunodeficiency 6.2 Allergic Disease & Atopy

7 Growth & Development

7.1 Developmental Milestones & Red Flags 7.2 Growth Assessment & Failure to Thrive 7.3 Corrected Age & Preterm Follow-Up 7.4 Developmental & Behavioral Disorders

8 Nutrition

8.1 Breastfeeding & Infant Feeding 8.2 Weaning & Malnutrition 8.3 Micronutrient Deficiencies (Rickets, Iron Deficiency)

9 Pediatric Emergencies I

9.1 Pediatric Basic & Advanced Life Support 9.2 Anaphylaxis & Allergic Emergencies 9.3 Poisoning & Toxicology

10 Pediatric Emergencies II

10.1 Septic Shock & the Critically Ill Child 10.2 Upper Airway Emergencies (Epiglottitis, Foreign Body) 10.3 Non-Accidental Injury & Safeguarding

11 Cardiology

11.1 Cyanotic Congenital Heart Disease 11.2 Acyanotic Congenital Heart Disease & Heart Failure 11.3 Innocent Murmurs & Cardiac Evaluation 11.4 Rheumatic Fever & Acquired Heart Disease

12 Respiratory

12.1 Asthma 12.2 Bronchiolitis & Croup 12.3 Foreign Body Aspiration & Other Airway Disorders

13 Gastroenterology

13.1 Pyloric Stenosis & Vomiting Disorders 13.2 Intussusception & the Surgical Abdomen 13.3 Celiac Disease & Malabsorption 13.4 Hirschsprung Disease & Biliary Atresia

14 Nephrology & Genitourinary

14.1 Nephrotic Syndrome 14.2 Glomerulonephritis & Hematuria 14.3 UTI, Enuresis & Genitourinary Anomalies

15 Hematology & Oncology

15.1 Pediatric Anemias (Iron Deficiency, Thalassemia) 15.2 Sickle Cell Disease 15.3 Leukemia & Childhood Malignancies (incl. Wilms Tumor) 15.4 Bleeding & Platelet Disorders (ITP) & G6PD Deficiency

16 Endocrinology

16.1 Diabetes Mellitus & Diabetic Ketoacidosis 16.2 Thyroid & Adrenal Disorders 16.3 Growth Disorders & Puberty

17 Neurology

17.1 Febrile Seizures 17.2 Epilepsy Syndromes & Status Epilepticus 17.3 Bacterial Meningitis & CNS Infections 17.4 Neuromuscular Disorders & Headache

18 Genetics, Dysmorphology & Metabolism

18.1 Chromosomal Disorders & Dysmorphology 18.2 Inheritance Patterns, Consanguinity & Inborn Errors of Metabolism

19 Fluids, Electrolytes & Pharmacology

19.1 Maintenance Fluids & Dehydration 19.2 Electrolyte Disturbances 19.3 Pediatric Pharmacology & Prescribing/Dosing

20 Dermatology, ENT, Ophthalmology & Musculoskeletal

20.1 Common Pediatric Dermatology 20.2 ENT Disorders 20.3 Ophthalmology (Strabismus, Red Eye, Leukocoria) 20.4 Musculoskeletal & Rheumatologic Disorders

21 Adolescent Medicine & Ethics

21.1 Adolescent Health & Puberty 21.2 Ethics, Consent & Professionalism in Pediatrics

22 Final Review & Exam Strategy

22.1 High-Yield Numbers, Mnemonics & Cross-Topic Review 22.2 Exam-Day Strategy & Time Management

3.2 Neonatal Hypoglycemia & Metabolic Problems

Key Takeaways Explain This Topic AI

The AAP and Pediatric Endocrine Society define neonatal hypoglycemia using different thresholds — there is no single universal cutoff, and both frameworks are testable.

Only at-risk infants (infants of diabetic mothers, SGA, LGA, late-preterm, and perinatally stressed infants) require routine protocol-driven glucose screening; well term infants without risk factors do not.

Dextrose gel applied to the buccal mucosa is now first-line adjunct therapy for mild-to-moderate asymptomatic hypoglycemia and reduces NICU admissions.

Severe or symptomatic hypoglycemia is treated with an IV dextrose bolus of 200 mg/kg followed by a continuous infusion titrated to a glucose infusion rate of 6-8 mg/kg/min.

Late hypocalcemia beyond 72 hours paired with a conotruncal heart defect should raise suspicion for DiGeorge syndrome, and polycythemia itself can cause hypoglycemia through increased red-cell glucose consumption.

Last updated: July 2026

Neonatal Glucose Homeostasis

In utero, the fetus receives a continuous transplacental glucose supply. At birth this supply stops abruptly, and the newborn must mount a coordinated hormonal response — a surge in glucagon and catecholamines with a fall in insulin — to drive glycogenolysis and gluconeogenesis until regular feeding is established. Failure of this transition, or an underlying disease process, produces neonatal hypoglycemia , one of the most heavily tested newborn topics because the correct threshold is genuinely debated in the literature.

Defining the Threshold: AAP vs. PES

There is no single universal glucose number that defines neonatal hypoglycemia for every infant — the exam expects familiarity with two different operational thresholds:

Body Threshold Rationale

American Academy of Pediatrics (AAP) Below 25 mg/dL at less than 4 hours of age; below 35 mg/dL at 4-24 hours; below 45 mg/dL at 24-48 hours; below 60 mg/dL after 48 hours Age-graded targets for screening and treating at-risk but otherwise well infants during the normal glucose nadir of transition

Pediatric Endocrine Society (PES) Below 50 mg/dL from birth to 48 hours; below 60 mg/dL after 48 hours A single, more conservative threshold intended to identify infants with a persistent hypoglycemia disorder (for example, hyperinsulinism) who need endocrine evaluation

A commonly used operational treatment target for at-risk or symptomatic infants in the first 24 hours is below 45 mg/dL (2.5 mmol/L) .

At-Risk Infants Who Require Routine Screening

Only specific at-risk groups need protocol-driven glucose screening — a well term infant with no risk factors does not:

Infant of a diabetic mother (IDM) — fetal hyperinsulinemia develops in response to maternal hyperglycemia; risk is highest in the first hours of life once the maternal glucose supply is cut off

  • Small-for-gestational-age (SGA) infants — reduced glycogen stores
  • Large-for-gestational-age (LGA) infants, even without maternal diabetes
  • Late-preterm infants (34 to 36 weeks 6 days) — immature counter-regulatory response
  • Infants with perinatal stress — asphyxia, sepsis, hypothermia, or significant respiratory distress

Screening protocol: check glucose within 30-60 minutes of the first feed, then per unit protocol every 3-6 hours for at least 24 hours, extended to 24-48 hours for SGA and late-preterm infants.

Clinical Signs

Hypoglycemia is frequently asymptomatic , which is exactly why at-risk infants are screened by protocol rather than tested only when symptomatic. When signs occur, they are nonspecific:

  • Jitteriness, tremors, a high-pitched cry, irritability
  • Poor feeding, lethargy, hypotonia
  • Temperature instability, apnea, tachypnea
  • Seizures in severe or prolonged hypoglycemia
  • Management
  • Asymptomatic, glucose above threshold: continue routine feeding and rescreen per protocol

Asymptomatic, mild-to-moderate hypoglycemia: enteral feed (breast milk or formula) with 40% dextrose gel massaged into the buccal mucosa — now a first-line adjunct shown to reduce NICU admission and mother-infant separation without affecting breastfeeding rates

Symptomatic or severe hypoglycemia (below about 20-25 mg/dL): IV dextrose bolus of 200 mg/kg (2 mL/kg of 10% dextrose) , followed by a continuous infusion at a glucose infusion rate (GIR) of 6-8 mg/kg/min , titrated upward if hypoglycemia persists

Hypoglycemia persisting beyond the first week of life , or requiring a GIR above 12 mg/kg/min to maintain euglycemia, should prompt evaluation for persistent hyperinsulinism — drawing a critical sample (insulin, cortisol, growth hormone, beta-hydroxybutyrate) at the time of a documented low glucose, and considering diazoxide

Worked Example: Calculating the Glucose Infusion Rate

A 3-kg infant with symptomatic hypoglycemia is started on IV 10% dextrose (D10W) at 13.5 mL/hour. Using GIR (mg/kg/min) = (percent dextrose x 10 x mL/hour) divided by (60 x weight in kg): GIR = (10 x 10 x 13.5) / (60 x 3) = 1,350 / 180 = 7.5 mg/kg/min, squarely within the 6-8 mg/kg/min target range. If the infant remains hypoglycemic despite this rate, the GIR is increased in small steps (typically by 2 mg/kg/min) rather than simply raising the dextrose concentration, since concentrations above 12.5% dextrose require central venous access because of the risk of peripheral vein sclerosis.

Point-of-care caveat: bedside glucometer readings can run 10-15% lower than a laboratory glucose-oxidase sample, particularly at low values. Any critically low point-of-care result that will guide a major treatment decision should be confirmed with a laboratory sample, though treatment should never be delayed while awaiting confirmation in a symptomatic infant.

  • Other Neonatal Metabolic Problems
  • Hypocalcemia

Early hypocalcemia (within 72 hours): seen with prematurity, IDM, and birth asphyxia — the abrupt loss of transplacental calcium combined with an immature parathyroid response. Total calcium below 8 mg/dL in term infants (below 7 mg/dL in preterm infants); ionized calcium below 4.4 mg/dL

Late hypocalcemia (after 72 hours): classically caused by high-phosphate cow's-milk-based formula , or by hypoparathyroidism — think DiGeorge syndrome (22q11.2 deletion) in an infant with hypocalcemic seizures plus a conotruncal cardiac defect

Signs: jitteriness, seizures, a prolonged QT interval; treatment is IV calcium gluconate 10% , given slowly with cardiac monitoring since extravasation causes tissue necrosis

Transient Tachypnea of the Newborn (TTN)

Caused by delayed clearance of fetal lung fluid . Risk factors include cesarean delivery without labor , macrosomia, and maternal diabetes. TTN presents within hours of birth with tachypnea and mild retractions; chest X-ray shows perihilar streaking and fluid in the interlobar fissures . It is self-limited, typically resolving within 24-72 hours with supportive oxygen — distinguish it from respiratory distress syndrome (preterm infant, ground-glass opacities, surfactant deficiency) and from sepsis-related respiratory distress.

Polycythemia

Defined as a venous hematocrit above 65% . Associated with IDM, SGA, delayed cord clamping, and the recipient twin in twin-twin transfusion syndrome . Hyperviscosity causes microvascular sludging, which is itself a cause of hypoglycemia through increased red-cell glucose consumption, along with plethora, respiratory distress, and jitteriness. Symptomatic infants with a hematocrit above 65%, or asymptomatic infants above 75%, may need a partial exchange transfusion ; mild cases are managed with hydration.